Rationale for a New Low-Dose Triple Single Pill Combination for the Treatment of Hypertension
References
- Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020; 396(10258): 1223–49. DOI: 10.1016/S0140-6736(20)30752-2
- Campbell NRC, Schutte AE, Varghese CV, Ordunez P, Zhang X, Khan T, et al. São Paulo call to action for the prevention and control of high blood pressure: 2020. The Journal of Clinical Hypertension. 2019; 21(12): 1744–52. DOI: 10.1111/jch.13741
- Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71(6): e13–e115. DOI: 10.1161/HYP.0000000000000065
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018; 39(33): 3021–104. DOI: 10.1093/eurheartj/ehy339
- Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA. 2013; 310(9): 959–68. DOI: 10.1001/jama.2013.184182
- Benjamin IJ, Kreutz R, Olsen MH, Schutte AE, Lopez-Jaramillo P, Frieden TR, et al. Fixed-dose combination antihypertensive medications. The Lancet. 2019; 394(10199): 637–8. DOI: 10.1016/S0140-6736(19)31629-0
- Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, et al. Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005–2016. Hypertension. 2020; 75(4): 973–81. DOI: 10.1161/HYPERTENSIONAHA.119.14360
- Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Journal of Hypertension. 2020; 38(6): 982–1004. DOI: 10.1097/HJH.0000000000002453
- World Health Organization. Guideline for the pharmacological treatment of hypertension in adults.
https://iris.who.int/bitstream/handle/10665/344424/9789240033986-eng.pdf?sequence=1 (accessed 31 January 2024). - Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. The American Journal of Medicine. 2009; 122(3): 290–300. DOI: 10.1016/j.amjmed.2008.09.038
- Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension. Journal of Hypertension. 2019; 37(9): 1768–74. DOI: 10.1097/HJH.0000000000002096
- Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SAE, Feagan BG. A Simplified Approach to the Treatment of Uncomplicated Hypertension. Hypertension. 2009; 53(4): 646–53. DOI: 10.1161/HYPERTENSIONAHA.108.123455
- Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andrejak M. Comparison of different therapeutic strategies in hypertension. Journal of Hypertension. 2004; 22(12): 2379–86. DOI: 10.1097/00004872-200412000-00021
- Bennett A, Chow CK, Chou M, Dehbi HM, Webster R, Salam A, et al. Efficacy and Safety of Quarter-Dose Blood Pressure–Lowering Agents. Hypertension. 2017; 70(1): 85–93. DOI: 10.1161/HYPERTENSIONAHA.117.09202
- Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003; 326(7404): 1427. DOI: 10.1136/bmj.326.7404.1427
- Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality. JAMA Cardiology. 2017; 2(7): 775–81. DOI: 10.1001/jamacardio.2017.1421
- Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Ramakrishnan R, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet. 2021; 397(10285): 1625–36. DOI: 10.1016/S0140-6736(21)00590-0
- Mahmud A, Feely J. Low-Dose Quadruple Antihypertensive Combination. Hypertension. 2007; 49(2): 272–5. DOI: 10.1161/01.HYP.0000254479.66645.a3
- Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS ONE. 2012; 7(7):
e41297 . DOI: 10.1371/journal.pone.0041297 - Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka. JAMA. 2018; 320(6): 566–579. DOI: 10.1001/jama.2018.10359
- Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. The Lancet. 2017; 389(10073): 1035–42. DOI: 10.1016/S0140-6736(17)30260-X
- Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. The Lancet. 2021; 398(10305): 1043–52. DOI: 10.1016/S0140-6736(21)01922-X
- Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide. Hypertension. 2009; 54(1): 32–9. DOI: 10.1161/HYPERTENSIONAHA.109.131300
- Chrysant SG, Izzo JL, Kereiakes DJ, Littlejohn T, Oparil S, Melino M, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. Journal of the American Society of Hypertension. 2012; 6(2): 132–41. DOI: 10.1016/j.jash.2011.09.003
- Mourad JJ, Amodeo C, de Champvallins M, Brzozowska-Villatte R, Asmar R. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension. Journal of Hypertension. 2017; 35(7): 1481–95. DOI: 10.1097/HJH.0000000000001359
- Neutel JM, Smith DHG. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovascular Therapeutics. 2013; 31(5): 251–8. DOI: 10.1111/1755-5922.12015
- Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and Characteristics of Angioedema Associated With Enalapril. Archives of Internal Medicine. 2005; 165(14): 1637–42. DOI: 10.1001/archinte.165.14.1637
- ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure — A network meta-analysis. International Journal of Cardiology. 2016; 217: 128–34. DOI: 10.1016/j.ijcard.2016.04.132
- Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews. 2014; 8:
CD009096 . DOI: 10.1002/14651858.CD009096.pub2 - Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. Mayo Clinic Proceedings. 2016; 91(1): 51–60. DOI: 10.1016/j.mayocp.2015.10.019
- Israili Z. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. Journal of Human Hypertension. 2000; 14(S1): S73–86. DOI: 10.1038/sj.jhh.1000991
- Sica DA. Calcium Channel Blocker Class Heterogeneity: Select Aspects of Pharmacokinetics and Pharmacodynamics. The Journal of Clinical Hypertension. 2005; 7: 21–6. DOI: 10.1111/j.1524-6175.2006.04482.x
- Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. Journal of Cellular and Molecular Medicine. 2017; 21(11): 2634–42. DOI: 10.1111/jcmm.13205
- Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015; 65(5): 1041–6. DOI: 10.1161/HYPERTENSIONAHA.114.05021
- Olde Engberink RHG, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJH. Effects of Thiazide-Type and Thiazide-Like Diuretics on Cardiovascular Events and Mortality. Hypertension. 2015; 65(5): 1033–40. DOI: 10.1161/HYPERTENSIONAHA.114.05122
- Roush GC, Holford TR, Guddati AK. Chlorthalidone Compared With Hydrochlorothiazide in Reducing Cardiovascular Events. Hypertension. 2012; 59(6): 1110–7. DOI: 10.1161/HYPERTENSIONAHA.112.191106
- Thomas J. A review of 10 years of experience with indapamide as an antihypertensive agent. Journal of Hypertension. 1985; 7(6 pt 2):
II152 . DOI: 10.1161/01.HYP.7.6_Pt_2.II152 - Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338:
b1665 . DOI: 10.1136/bmj.b1665 - Khin MU. FDA Briefing Document. Cardiovascular and Renal Drugs Advisory Committee Meeting September 10, 2014 To discuss the potential clinical utility of fixed combination prescription drugs composed of an antihypertensive drug, aspirin, and a statin administered to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in patients with a history of cardiovascular disease. 2014.
- ClinicalTrials.gov. Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension (GMRx2_PCT).
https://classic.clinicaltrials.gov/ct2/show/NCT04518306?term=gmrx2&cond=gmrx2&draw=2&rank=1 (accessed 31 January 2024). - ClinicalTrials.gov. Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (GMRx2_ACT).
https://clinicaltrials.gov/study/NCT04518293?tab=results (accessed 31 January 2024). - Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy. Journal of Hypertension. 2019; 37(8): 1567–73. DOI: 10.1097/HJH.0000000000002089
- Lasserson DS, Buclin T, Glasziou PJH. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart. 2011; 97(21): 1771–5. DOI: 10.1136/hrt.2010.221473
- Evaluation of pharmacokinetic drug interaction between telmisartan, amlodipine and indapamide when administered together as a fixed-dose combination in GMRx2. Available from: EudraCT No.: 2020-000648-68. Sponsor’s Study No.: GMRX2_Interaction CPA 527-20.
- Effect of food on pharmacokinetics of telmisartan, amlodipine, and indapamide fixed-dose combination (GMRx2). Available from: EudraCT No.: 2021-002863-23. Sponsor’s Study No.: GMRX2_Food effect_01 CPA 533-21.
- Anderson CS, Rodgers A, de Silva HA, Martins SO, Klijn CJ, Senanayake B, et al. Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress. International Journal of Stroke. 2022; 17(10): 1156–1162. DOI: 10.1177/17474930211068671
- Salam A, Huffman MD, Kanukula R, Hari Prasad E, Sharma A, Heller DJ, et al. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost. The Journal of Clinical Hypertension. 2020; 22(10): 1769–1779. DOI: 10.1111/jch.14009
- Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. The Lancet. 2016; 387(10013): 61–9. DOI: 10.1016/S0140-6736(15)00469-9
- Adeloye D, Basquill C. Estimating the Prevalence and Awareness Rates of Hypertension in Africa: A Systematic Analysis. PLoS ONE. 2014; 9(8):
e104300 . DOI: 10.1371/journal.pone.0104300 - Dzudie A, Rayner B, Ojji D, Schutte AE, Twagirumukiza M, Damasceno A, et al. Roadmap to achieve 25% hypertension control in Africa by 2025. Cardiovascular Journal of Africa. 2017; 28(4): 262–272. DOI: 10.5830/CVJA-2017-040
- Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products in the treatment of hypertension. EMA/CHMP/29947/2013/Rev. 4. 23 June 2016; 2016.
- Peters R, Xu Y, Fitzgerald O, Aung HL, Beckett N, Bulpitt C, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. European Heart Journal. 2022; 43(48): 4980–90. DOI: 10.1093/eurheartj/ehac584
- World Health Organization. Global report on hypertension: the race against a silent killer.
https://www.who.int/publications/i/item/9789240081062 (accessed 31 January 2024). - Hong SJ, Sung KC, Lim SW, Kim SY, Kim W, et al. Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study. Drug Design, Development and Therapy. 2020; 14: 5735–5746. DOI: 10.2147/DDDT.S286586
DOI: https://doi.org/10.5334/gh.1283 | Journal eISSN: 2211-8179
Language: English
Submitted on: Jun 23, 2023
Accepted on: Dec 4, 2023
Published on: Feb 14, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2024 Anthony Rodgers, Abdul Salam, William Cushman, Asita de Silva, Gian Luca Di Tanna, Sonali R. Gnanenthiran, Diederick Grobbee, Krzysztof Narkiewicz, Dike Ojji, Suzanne Oparil, Neil Poulter, Markus P. Schlaich, Aletta E. Schutte, Wilko Spiering, Bryan Williams, Jackson T. Wright, Paul Whelton, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.